P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)

por Gulrajani, Michael, Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd
Publicado 2023

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

por Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Gulrajani, Michael, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd
Publicado 2023

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

por Jurczak, Wojciech, Elmusharaf, Nagah, Fox, Christopher P., Townsend, William, Paulovich, Amanda G., Whiteaker, Jeffrey R., Krantz, Fanny, Wun, Chuan-Chuan, Parr, Graeme, Sharma, Shringi, Munugalavadla, Veerendra, Manwani, Richa, Dean, Emma, Munir, Talha
Publicado 2023